Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Src Antibody - Primary antibody, specific to Src, Rabbit IgG

    Application:
  • WB
Features and benefits
  • Host species: Rabbit
  • Species reactivity(Reacts with): Human,Mouse,Rat
  • Isotype: Rabbit IgG
  • Conjugation: Unconjugated
Item Number
Ab129134
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab129134-10μl
10μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$69.90
Ab129134-50μl
50μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$199.90
Ab129134-100μl
100μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$309.90
Ab129134-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,199.90
Add to Wish List Compare
Bulk Order  DATASHEET

Recombinant; Rabbit anti Human Src Antibody; WB; Unconjugated

View related series
Click to view target information: SRC
Accession#:P12931 Gene ID:6714 Src

Basic Description

Product NameSrc Antibody - Primary antibody, specific to Src, Rabbit IgG
SynonymsASV1; THC6; c-SRC; p60-Src; SRC; ASV; c-Src; EC 2.7.10; EC 2.7.10.2; pp60c-src; Rous sarcoma; RSVgp4; Src; tyrosine kinase pp60c-src; tyrosine-protein kinase SRC-1; v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog; v-src sarcoma (Schmidt-Ru
Specifications & PurityExactAb™, Validated, KD, Recombinant, Lot by Lot
Biochemical and Physiological MechanismsActs as a receptor for sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH). Associates with the smoothened protein (SMO) to transduce the hedgehog's proteins signal. Seems to have a tumor suppressor function, as inactivation of this prot
Host speciesRabbit
SpecificitySrc
ImmunogenA synthetic peptide derived from human Src (AA 250-536)
Positive ControlWB: HeLa, Jurkat, Hep G2, MCF7, HEK293, A431, NIH/3T3 and C6 cell lysates.
ConjugationUnconjugated
GradeExactAb™, KD Validation, Recombinant, Validated
Product Description

Rabbit anti Human Src Antibody, Recombinant, could be used for WB and so on.

Product Properties

IsotypeRabbit IgG
Light Chain Typekappa
SDS-PAGE150 kDa
Purification MethodProtein A purified
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant Src Antibody (Ab129134) - Western Blot
All lanes: Recombinant Src Antibody (Ab129134) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 60 kDa
Observed band size: 59 kDa
Exposure time: 100.0 s

Associated Targets(Human)

SRC Tclin Proto-oncogene tyrosine-protein kinase Src (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SRC Tclin Tyrosine-protein kinase SRC (10310 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tclin VEGF-receptor 2 and tyrosine-protein kinase SRC (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tclin Calmodulin/Proto-oncogene tyrosine-protein kinase Src (2 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tclin VHL/SRC (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tclin Src/Lck kinase (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Application

ApplicationDilution info
WB1/1000 - 1/2000

">

1/1000 - 1/2000

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

 SDS

 Specification Sheet

References

1. Sundaramoorthi R, Shakespeare WC, Keenan TP, Metcalf CA, Wang Y, Mani U, Taylor M, Liu S, Bohacek RS, Narula SS, Dalgarno DC, van Schravandijk MR, Violette SM, Liou S, Adams S, Ram MK, Keats JA, Weigle M, Sawyer TK, Weigele M..  (2003)  Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues..  Bioorg Med Chem Lett,  13  (18): (3063-3066).  [PMID:12941334] [10.1016/s0960-894x(03)00647-4]
2. Wang Y, Metcalf CA, Shakespeare WC, Sundaramoorthi R, Keenan TP, Bohacek RS, van Schravendijk MR, Violette SM, Narula SS, Dalgarno DC, Haraldson C, Keats J, Liou S, Mani U, Pradeepan S, Ram M, Adams S, Weigele M, Sawyer TK..  (2003)  Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases..  Bioorg Med Chem Lett,  13  (18): (3067-3070).  [PMID:12941335] [10.1016/s0960-894x(03)00648-6]
3. Burke TR, Barchi JJ, George C, Wolf G, Shoelson SE, Yan X..  (1995)  Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors..  J Med Chem,  38  (8): (1386-1396).  [PMID:7537333] [10.1021/jm00008a017]
4. Plummer MS, Holland DR, Shahripour A, Lunney EA, Fergus JH, Marks JS, McConnell P, Mueller WT, Sawyer TK..  (1997)  Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand..  J Med Chem,  40  (23): (3719-3725).  [PMID:9371236] [10.1021/jm970402q]
5. Eaton SR, Cody WL, Doherty AM, Holland DR, Panek RL, Lu GH, Dahring TK, Rose DR..  (1998)  Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity..  J Med Chem,  41  (22): (4329-4342).  [PMID:9784108] [10.1021/jm9802766]
6. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA..  (1998)  Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors..  J Med Chem,  41  (5): (742-751).  [PMID:9513602] [10.1021/jm970641d]
7. Ettmayer P, France D, Gounarides J, Jarosinski M, Martin MS, Rondeau JM, Sabio M, Topiol S, Weidmann B, Zurini M, Bair KW..  (1999)  Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1)..  J Med Chem,  42  (6): (971-980).  [PMID:10090780] [10.1021/jm9811007]
8. Thompson AM, Connolly CJ, Hamby JM, Boushelle S, Hartl BG, Amar AM, Kraker AJ, Driscoll DL, Steinkampf RW, Patmore SJ, Vincent PW, Roberts BJ, Elliott WL, Klohs W, Leopold WR, Showalter HD, Denny WA..  (2000)  3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase..  J Med Chem,  43  (22): (4200-4211).  [PMID:11063616] [10.1021/jm000161d]
9. Lesuisse D, Lange G, Deprez P, Bénard D, Schoot B, Delettre G, Marquette JP, Broto P, Jean-Baptiste V, Bichet P, Sarubbi E, Mandine E..  (2002)  SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2..  J Med Chem,  45  (12): (2379-2387).  [PMID:12036348] [10.1021/jm010927p]
10. Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW..  (2000)  Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors..  Biochem Pharmacol,  60  (7): (885-898).  [PMID:10974196] [10.1016/s0006-2952(00)00405-6]
11. Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J.  (2001)  The DNA sequence and comparative analysis of human chromosome 20..  Nature,  414  (6866): (865-71).  [PMID:11780052] [10.1021/op500134e]
12. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A et al..  (1996)  (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta..  J Med Chem,  39  (14): (2664-71).  [PMID:8709095] [10.1021/op500134e]
13. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al..  (2012)  7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes..  J Med Chem,  55  (1): (403-13).  [PMID:22136433] [10.1021/op500134e]
14. Soth M, Hermann JC, Yee C, Alam M, Barnett JW, Berry P, Browner MF, Frank K, Frauchiger S, Harris S et al..  (2013)  3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models..  J Med Chem,  56  (1): (345-56).  [PMID:23214979] [10.1021/op500134e]
15. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M et al..  (2010)  Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)..  J Med Chem,  53  (5): (2239-49).  [PMID:20151677] [10.1021/op500134e]
16. Xu W, Harrison SC, Eck MJ.  (1997)  Three-dimensional structure of the tyrosine kinase c-Src..  Nature,  385  (6617): (595-602).  [PMID:9024657] [10.1021/op500134e]
17. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW et al..  (2005)  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants..  Cancer Res,  65  (11): (4500-5).  [PMID:15930265] [10.1021/op500134e]
18. Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P et al..  (2006)  Allosteric inhibitors of Bcr-abl-dependent cell proliferation..  Nat Chem Biol,  2  (2): (95-102).  [PMID:16415863] [10.1021/op500134e]
19. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al..  (2007)  Patterns of somatic mutation in human cancer genomes..  Nature,  446  (7132): (153-8).  [PMID:17344846] [10.1021/op500134e]
20. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al..  (2004)  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays..  J Med Chem,  47  (27): (6658-61).  [PMID:15615512] [10.1021/op500134e]
21. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M et al..  (2009)  Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells..  Leukemia,  23  (3): (477-85).  [PMID:19039322] [10.1021/op500134e]
22. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, Goddard S, Gobert-Gosse S, Corbo L.  (2008)  Regulation of estrogen rapid signaling through arginine methylation by PRMT1..  Mol Cell,  31  (2): (212-21).  [PMID:18657504] [10.1021/op500134e]
23. Manley PW, Furet P, Bold G, Brüggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A et al..  (2002)  Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors..  J Med Chem,  45  (26): (5687-93).  [PMID:12477352] [10.1021/op500134e]
24. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A et al..  (2006)  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor..  J Med Chem,  49  (22): (6465-88).  [PMID:17064066] [10.1021/op500134e]
25. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J et al..  (2007)  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK..  Proc Natl Acad Sci USA,  104  (1): (270-5).  [PMID:17185414] [10.1021/op500134e]
26. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ.  (2007)  Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one..  J Biol Chem,  282  (33): (24463-70).  [PMID:17562705] [10.1021/op500134e]
27. Huang H, Jia Q, Ma J, Qin G, Chen Y, Xi Y, Lin L, Zhu W, Ding J, Jiang H et al..  (2009)  Discovering novel quercetin-3-O-amino acid-esters as a new class of Src tyrosine kinase inhibitors..  Eur J Med Chem,  44  (5): (1982-8).  [PMID:19041163] [10.1021/op500134e]
28. Conchon E, Anizon F, Aboab B, Golsteyn RM, Léonce S, Pfeiffer B, Prudhomme M.  (2008)  Synthesis, checkpoint kinase 1 inhibitory properties and in vitro antiproliferative activities of new pyrrolocarbazoles..  Bioorg Med Chem,  16  (8): (4419-30).  [PMID:18321713] [10.1021/op500134e]
29. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al..  (2006)  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity..  J Med Chem,  49  (12): (3563-80).  [PMID:16759099] [10.1021/op500134e]
30. Wang WY, Hsieh PW, Wu YC, Wu CC.  (2007)  Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity..  Biochem Pharmacol,  74  (4): (601-11).  [PMID:17601492] [10.1021/op500134e]
31. Gavrin LK, Green N, Hu Y, Janz K, Kaila N, Li HQ, Tam SY, Thomason JR, Gopalsamy A, Ciszewski G et al..  (2005)  Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships..  Bioorg Med Chem Lett,  15  (23): (5288-92).  [PMID:16165349] [10.1021/op500134e]
32. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al..  (2009)  p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression..  J Med Chem,  52  (20): (6257-69).  [PMID:19772287] [10.1021/op500134e]
33. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al..  (2011)  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase..  J Med Chem,  54  (20): (7066-83).  [PMID:21936542] [10.1021/op500134e]
34. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al..  (2013)  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design..  ACS Med Chem Lett,  4  (1): (91-7).  [PMID:24900568] [10.1021/op500134e]
35. Pevet I, Brulé C, Tizot A, Gohier A, Cruzalegui F, Boutin JA, Goldstein S.  (2011)  Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors..  Bioorg Med Chem,  19  (8): (2517-28).  [PMID:21459579] [10.1021/op500134e]
36. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG.  (2012)  KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer..  Breast Cancer Res Treat,  132  (2): (391-409).  [PMID:21509526] [10.1021/op500134e]
37. Machrouhi F, Ouhamou N, Laderoute K, Calaoagan J, Bukhtiyarova M, Ehrlich PJ, Klon AE.  (2010)  The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity..  Bioorg Med Chem Lett,  20  (22): (6394-9).  [PMID:20932747] [10.1021/op500134e]
38. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA.  (2008)  Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases..  Nat Chem Biol,  4  (11): (691-9).  [PMID:18849971] [10.1021/op500134e]
39. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al..  (2009)  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)..  Blood,  114  (14): (2984-92).  [PMID:19654408] [10.1021/op500134e]
40. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM et al..  (2005)  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580..  Proc Natl Acad Sci USA,  102  (44): (16078-83).  [PMID:16249345] [10.1021/op500134e]
41. Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y et al..  (2015)  Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)..  J Med Chem,  58  (1): (183-96).  [PMID:25075558] [10.1021/op500134e]
42. Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O et al..  (2013)  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3..  J Med Chem,  56  (20): (8032-48).  [PMID:24044867] [10.1021/op500134e]
43. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS.  (2011)  Identification and characterization of a novel integrin-linked kinase inhibitor..  J Med Chem,  54  (18): (6364-74).  [PMID:21823616] [10.1021/op500134e]
44. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C et al..  (2007)  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors..  Nat Biotechnol,  25  (9): (1035-44).  [PMID:17721511] [10.1021/op500134e]
45. Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM.  (2009)  Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells..  J Med Chem,  52  (10): (3191-204).  [PMID:19397322] [10.1021/op500134e]
46. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C.  (2009)  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4)..  J Med Chem,  52  (20): (6433-46).  [PMID:19788238] [10.1021/op500134e]
47. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, Hutchaleelaha A, Hollenbach SJ, Abe K, Giese NA et al..  (2002)  Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family..  J Med Chem,  45  (17): (3772-93).  [PMID:12166950] [10.1021/op500134e]
48. Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA.  (1997)  In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor..  J Pharmacol Exp Ther,  283  (3): (1433-44).  [PMID:9400019] [10.1021/op500134e]
49. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al..  (2012)  Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent..  J Med Chem,  55  (2): (903-13).  [PMID:22148921] [10.1021/op500134e]
50. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM.  (2009)  Inhibitor hijacking of Akt activation..  Nat Chem Biol,  5  (7): (484-93).  [PMID:19465931] [10.1021/op500134e]
51. Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S et al..  (2011)  Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group..  Bioorg Med Chem,  19  (21): (6274-84).  [PMID:21967808] [10.1021/op500134e]
52. Li B, Cociorva OM, Nomanbhoy T, Weissig H, Li Q, Nakamura K, Liyanage M, Zhang MC, Shih AY, Aban A et al..  (2013)  Hit-to-lead optimization and kinase selectivity of imidazo[1,2-a]quinoxalin-4-amine derived JNK1 inhibitors..  Bioorg Med Chem Lett,  23  (18): (5217-22).  [PMID:23916259] [10.1021/op500134e]
53. Cai X, Zhai HX, Wang J, Forrester J, Qu H, Yin L, Lai CJ, Bao R, Qian C.  (2010)  Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer..  J Med Chem,  53  (5): (2000-9).  [PMID:20143778] [10.1021/op500134e]
54. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR et al..  (2016)  Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia..  N Engl J Med,  374  (4): (323-32).  [PMID:26641137] [10.1021/op500134e]
55. Crespan E, Radi M, Zanoli S, Schenone S, Botta M, Maga G.  (2010)  Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms..  Bioorg Med Chem,  18  (11): (3999-4008).  [PMID:20451394] [10.1021/op500134e]
56. Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J et al..  (2016)  Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase..  J Med Chem,  59  (10): (4948-64).  [PMID:27144831] [10.1021/op500134e]
57. Fraser C, Dawson JC, Dowling R, Houston DR, Weiss JT, Munro AF, Muir M, Harrington L, Webster SP, Frame MC et al..  (2016)  Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase..  J Med Chem,  59  (10): (4697-710).  [PMID:27115835] [10.1021/op500134e]
58. Patel S, Cohen F, Dean BJ, De La Torre K, Deshmukh G, Estrada AA, Ghosh AS, Gibbons P, Gustafson A, Huestis MP et al..  (2015)  Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models..  J Med Chem,  58  (1): (401-18).  [PMID:25341110] [10.1021/op500134e]
59. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J et al..  (2009)  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control..  J Med Chem,  52  (20): (6362-8).  [PMID:19827834] [10.1021/op500134e]
60. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al..  (2011)  Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis..  Bioorg Med Chem Lett,  21  (21): (6258-63).  [PMID:21958547] [10.1021/op500134e]
61. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al..  (2015)  Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders..  J Med Chem,  58  (23): (9154-70).  [PMID:26509640] [10.1021/op500134e]
62. Huang Z, Li H, Zhang Q, Lu F, Hong M, Zhang Z, Guo X, Zhu Y, Li S, Liu H.  (2017)  Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis..  ACS Med Chem Lett,  8  (11): (1142-1147).  [PMID:29152045] [10.1021/op500134e]
63. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G et al..  (2017)  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors..  Bioorg Med Chem,  25  (4): (1320-1328).  [PMID:28038940] [10.1021/op500134e]
64. Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J et al..  (2017)  Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors..  J Med Chem,  60  (15): (6516-6527).  [PMID:28665128] [10.1021/op500134e]
65. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al..  (2015)  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies..  J Med Chem,  58  (21): (8373-86).  [PMID:26505898] [10.1021/op500134e]
66. Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M et al..  (2015)  Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma..  Cancer Cell,  27  (1): (85-96).  [PMID:25500121] [10.1021/op500134e]
67. Watterson SH, De Lucca GV, Shi Q, Langevine CM, Liu Q, Batt DG, Beaudoin Bertrand M, Gong H, Dai J, Yip S et al..  (2016)  Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers..  J Med Chem,  59  (19): (9173-9200).  [PMID:27583770] [10.1021/op500134e]
68. Gucký T, Řezníčková E, Radošová Muchová T, Jorda R, Klejová Z, Malínková V, Berka K, Bazgier V, Ajani H, Lepšík M et al..  (2018)  Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl- N6-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations..  J Med Chem,  61  (9): (3855-3869).  [PMID:29672049] [10.1021/op500134e]
69. Pippione AC, Sainas S, Federico A, Lupino E, Piccinini M, Kubbutat M, Contreras JM, Morice C, Barge A, Ducime A et al..  (2018)  N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK..  Medchemcomm,  9  (6): (963-968).  [PMID:30108985] [10.1039/C8MD00068A]
70. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al..  (2015)  Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)..  J Med Chem,  58  (20): (8182-99).  [PMID:26431428] [10.1021/op500134e]
71. Smolinski MP, Bu Y, Clements J, Gelman IH, Hegab T, Cutler DL, Fang JWS, Fetterly G, Kwan R, Barnett A et al..  (2018)  Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)..  J Med Chem,  61  (11): (4704-4719).  [PMID:29617135] [10.1021/op500134e]
72. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al..  (2018)  Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model..  J Med Chem,  61  (24): (11398-11414).  [PMID:30480444] [10.1021/op500134e]
73. Qi B, Yang Y, Gong G, He H, Yue X, Xu X, Hu Y, Li J, Chen T, Wan X et al..  (2019)  Discovery of N1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment..  Eur J Med Chem,  163  (13): (10-27).  [PMID:30503936] [10.1021/op500134e]
74. Zhang H, Xu L, Qin X, Chen X, Cong H, Hu L, Chen L, Miao Z, Zhang W, Cai Z et al..  (2019)  N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy..  J Med Chem,  62  (14): (6665-6681).  [PMID:31095385] [10.1021/op500134e]
75. Smith CR, Dougan DR, Komandla M, Kanouni T, Knight B, Lawson JD, Sabat M, Taylor ER, Vu P, Wyrick C.  (2015)  Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase..  J Med Chem,  58  (14): (5437-44).  [PMID:26087137] [10.1021/op500134e]
76. Yao X, Sun X, Jin S, Yang L, Xu H, Rao Y.  (2019)  Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis..  J Med Chem,  62  (14): (6561-6574).  [PMID:31260299] [10.1021/op500134e]
77. Pomel V, Klicic J, Covini D, Church DD, Shaw JP, Roulin K, Burgat-Charvillon F, Valognes D, Camps M, Chabert C et al..  (2006)  Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma..  J Med Chem,  49  (13): (3857-71).  [PMID:16789742] [10.1021/op500134e]
78. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y et al..  (2013)  Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib..  J Med Chem,  56  (3): (879-94).  [PMID:23301703] [10.1021/op500134e]
79. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al..  (2020)  Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R..  J Med Chem,  71  (13): (1755-70).  [PMID:32787110] [10.1021/acs.jmedchem.0c00936]
80. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H.  (2018)  A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy..  Eur J Med Chem,  144  (13): (1-28).  [PMID:29247857] [10.1021/op500134e]
81. Erki Enkvist, Darja Lavogina, Gerda Raidaru, Angela Vaasa, Indrek Viil, Marje Lust, Kaido Viht, Asko Uri,.  (2006-11-28)  Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases..  Journal of medicinal chemistry,  49  ((24)): ( 7150-7159 ).  [PMID:17125267]
82. Bianca Sperl,Markus H J Seifert,Thorsten Berg.  (2009-05-12)  Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains..  Bioorganic & medicinal chemistry letters,  19  ((12)): (3305-3309).  [PMID:19427202]
83. V Kameshwara Rao,Bhupender S Chhikara,Amir Nasrolahi Shirazi,Rakesh Tiwari,Keykavous Parang,Anil Kumar.  (2011-05-27)  3-substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities..  Bioorganic & medicinal chemistry letters,  21  ((12)): (3511-3514).  [PMID:21612925]
84. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong.  (2013-04-23)  Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant..  Journal of medicinal chemistry,  56  ((9)): (3531-3545).  [PMID:23600806]
85. Ajit Dhananjay Jagtap,Pei-Teh Chang,Jia-Rong Liu,Hsiao-Chun Wang,Nagendra B Kondekar,Li-Jiuan Shen,Hsiang-Wen Tseng,Grace Shiahuy Chen,Ji-Wang Chern.  (2014-08-05)  Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia..  European journal of medicinal chemistry,  85  (268-288).  [PMID:25089810]
86. Xin Cao,Qi-Dong You,Zhi-Yu Li,Qing-Long Guo,Jing Shang,Ming Yan,Ji-Wang Chern,Men-Ling Chen.  (2008-05-20)  Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase..  Bioorganic & medicinal chemistry,  16  ((11)): (5890-5898).  [PMID:18485715]
87. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis..  Bioorg Med Chem Lett,  14  (13): (3595-3599).  [PMID:15177482] [10.1016/j.bmcl.2004.03.106]
88. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity..  Bioorg Med Chem Lett,  14  (13): (3601-3605).  [PMID:15177483] [10.1016/j.bmcl.2004.03.111]
89. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G..  (2006)  Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity..  Bioorg Med Chem Lett,  16  (2): (262-266).  [PMID:16249085] [10.1016/j.bmcl.2005.10.015]
90. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G..  (2006)  Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors..  J Med Chem,  49  (15): (4455-4458).  [PMID:16854050] [10.1021/jm060465l]
91. Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ..  (2006)  Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2..  J Med Chem,  49  (13): (3766-3769).  [PMID:16789733] [10.1021/jm060347y]
92. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cee VJ, Chai L, Deak HL, Epstein LF, Faust T, Gallant P, Geuns-Meyer SD, Gore A, Gu Y, Henkle B, Hodous BL, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, Masse CE, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, White RD, Zhao H, Zhu L, Zhu X..  (2006)  Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity..  J Med Chem,  49  (19): (5671-5686).  [PMID:16970394] [10.1021/jm0605482]
93. Hu Y, Green N, Gavrin LK, Janz K, Kaila N, Li HQ, Thomason JR, Cuozzo JW, Hall JP, Hsu S, Nickerson-Nutter C, Telliez JB, Lin LL, Tam S..  (2006)  Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis..  Bioorg Med Chem Lett,  16  (23): (6067-6072).  [PMID:16973359] [10.1016/j.bmcl.2006.08.102]
94. Aronov AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ, Germann UA, Green J, Hale MR, Jacobs M, Janetka JW, Maltais F, Martinez-Botella G, Namchuk MN, Straub J, Tang Q, Xie X..  (2007)  Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors..  J Med Chem,  50  (6): (1280-1287).  [PMID:17300186] [10.1021/jm061381f]
95. Mukaiyama H, Nishimura T, Kobayashi S, Ozawa T, Kamada N, Komatsu Y, Kikuchi S, Oonota H, Kusama H..  (2007)  Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke..  Bioorg Med Chem,  15  (2): (868-885).  [PMID:17095233] [10.1016/j.bmc.2006.10.041]
96. Dinges J, Albert DH, Arnold LD, Ashworth KL, Akritopoulou-Zanze I, Bousquet PF, Bouska JJ, Cunha GA, Davidsen SK, Diaz GJ, Djuric SW, Gasiecki AF, Gintant GA, Gracias VJ, Harris CM, Houseman KA, Hutchins CW, Johnson EF, Li H, Marcotte PA, Martin RL, Michaelides MR, Nyein M, Sowin TJ, Su Z, Tapang PH, Xia Z, Zhang HQ..  (2007)  1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel..  J Med Chem,  50  (9): (2011-2029).  [PMID:17425296] [10.1021/jm061223o]
97. Bruno O, Brullo C, Bondavalli F, Schenone S, Ranise A, Arduino N, Bertolotto MB, Montecucco F, Ottonello L, Dallegri F, Tognolini M, Ballabeni V, Bertoni S, Barocelli E..  (2007)  Synthesis and biological evaluation of N-pyrazolyl-N'-alkyl/benzyl/phenylureas: a new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis..  J Med Chem,  50  (15): (3618-3626).  [PMID:17608466] [10.1021/jm0704402]
98. Potashman MH, Bready J, Coxon A, DeMelfi TM, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange JC, Kaufman SA, Kendall R, Kim JL, Kumar GN, Long AM, Neervannan S, Patel VF, Polverino A, Rose P, Plas Sv, Whittington D, Zanon R, Zhao H..  (2007)  Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors..  J Med Chem,  50  (18): (4351-4373).  [PMID:17696416] [10.1021/jm070034i]
99. Green N, Hu Y, Janz K, Li HQ, Kaila N, Guler S, Thomason J, Joseph-McCarthy D, Tam SY, Hotchandani R, Wu J, Huang A, Wang Q, Leung L, Pelker J, Marusic S, Hsu S, Telliez JB, Hall JP, Cuozzo JW, Lin LL..  (2007)  Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles..  J Med Chem,  50  (19): (4728-4745).  [PMID:17715908] [10.1021/jm070436q]
100. Conchon E, Anizon F, Aboab B, Prudhomme M..  (2007)  Synthesis and biological activities of new checkpoint kinase 1 inhibitors structurally related to granulatimide..  J Med Chem,  50  (19): (4669-4680).  [PMID:17722905] [10.1021/jm070664k]
101. Hugon B, Anizon F, Bailly C, Golsteyn RM, Pierré A, Léonce S, Hickman J, Pfeiffer B, Prudhomme M..  (2007)  Synthesis and biological activities of isogranulatimide analogues..  Bioorg Med Chem,  15  (17): (5965-5980).  [PMID:17582773] [10.1016/j.bmc.2007.05.073]
102. Graham Robinett R, Freemerman AJ, Skinner MA, Shewchuk L, Lackey K..  (2007)  The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors..  Bioorg Med Chem Lett,  17  (21): (5886-5893).  [PMID:17884497] [10.1016/j.bmcl.2007.07.104]
103. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M..  (2007)  Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice..  J Med Chem,  50  (23): (5579-5588).  [PMID:17929792] [10.1021/jm061449r]
104. Ji Z, Ahmed AA, Albert DH, Bouska JJ, Bousquet PF, Cunha GA, Diaz G, Glaser KB, Guo J, Harris CM, Li J, Marcotte PA, Moskey MD, Oie T, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR..  (2008)  3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases..  J Med Chem,  51  (5): (1231-1241).  [PMID:18260617] [10.1021/jm701096v]
105. Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG..  (2008)  Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity..  J Med Chem,  51  (6): (1637-1648).  [PMID:18278858] [10.1021/jm701095m]
106. Palanki MS, Akiyama H, Campochiaro P, Cao J, Chow CP, Dellamary L, Doukas J, Fine R, Gritzen C, Hood JD, Hu S, Kachi S, Kang X, Klebansky B, Kousba A, Lohse D, Mak CC, Martin M, McPherson A, Pathak VP, Renick J, Soll R, Umeda N, Yee S, Yokoi K, Zeng B, Zhu H, Noronha G..  (2008)  Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration..  J Med Chem,  51  (6): (1546-1559).  [PMID:18311895] [10.1021/jm7011276]
107. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X..  (2008)  Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation..  J Med Chem,  51  (6): (1681-1694).  [PMID:18321037] [10.1021/jm7010996]
108. Conchon E, Anizon F, Aboab B, Golsteyn RM, Léonce S, Pfeiffer B, Prudhomme M..  (2008)  Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3-diones, and 2-aminopyridazino[3,4-a]pyrrolo[3,4-c]carbazole-1,3,4,7-tetraone..  Eur J Med Chem,  43  (2): (282-292).  [PMID:17502122] [10.1016/j.ejmech.2007.03.026]
109. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J..  (2007)  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling..  Proc Natl Acad Sci U S A,  104  (50): (19936-19941).  [PMID:18077425] [10.1073/pnas.0707498104]
110. Chu JJ, Yang PL..  (2007)  c-Src protein kinase inhibitors block assembly and maturation of dengue virus..  Proc Natl Acad Sci U S A,  104  (9): (3520-3525).  [PMID:17360676] [10.1073/pnas.0611681104]
111. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT..  (2007)  Cellular characterization of a novel focal adhesion kinase inhibitor..  J Biol Chem,  282  (20): (14845-14852).  [PMID:17395594] [10.1074/jbc.m606695200]
112. Kunz RK, Rumfelt S, Chen N, Zhang D, Tasker AS, Bürli R, Hungate R, Yu V, Nguyen Y, Whittington DA, Meagher KL, Plant M, Tudor Y, Schrag M, Xu Y, Ng GY, Hu E..  (2008)  Discovery of amido-benzisoxazoles as potent c-Kit inhibitors..  Bioorg Med Chem Lett,  18  (18): (5115-5117).  [PMID:18723346] [10.1016/j.bmcl.2008.07.111]
113. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107] [10.1021/jm800986w]
114. Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Miyazawa K, Misawa K, Ohnota H, Isaji M..  (2009)  Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors..  Bioorg Med Chem,  17  (1): (284-294).  [PMID:19010686] [10.1016/j.bmc.2008.10.070]
115. Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, Greco R, Huang X, Joseph-McCarthy D, Kelly MF, Kirisits M, Lee J, Li Y, Morgan P, Stock JR, Tsao DH, Wissner A, Yang X, Chaudhary D..  (2008)  Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors..  J Med Chem,  51  (19): (5958-5963).  [PMID:18783200] [10.1021/jm800214a]
116. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG..  (2008)  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth..  J Med Chem,  51  (23): (7405-7416).  [PMID:18989950] [10.1021/jm800483v]
117. Huang H, Hutta DA, Rinker JM, Hu H, Parsons WH, Schubert C, DesJarlais RL, Crysler CS, Chaikin MA, Donatelli RR, Chen Y, Cheng D, Zhou Z, Yurkow E, Manthey CL, Player MR..  (2009)  Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors..  J Med Chem,  52  (4): (1081-1099).  [PMID:19193011] [10.1021/jm801406h]
118. Lee K, Kim J, Jeong KW, Lee KW, Lee Y, Song JY, Kim MS, Lee GS, Kim Y..  (2009)  Structure-based virtual screening of Src kinase inhibitors..  Bioorg Med Chem,  17  (8): (3152-3161).  [PMID:19321350] [10.1016/j.bmc.2009.02.054]
119. Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM..  (2009)  Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening..  Bioorg Med Chem Lett,  19  (13): (3598-3601).  [PMID:19447617] [10.1016/j.bmcl.2009.04.138]
120. Huang WS, Zhu X, Wang Y, Azam M, Wen D, Sundaramoorthi R, Thomas RM, Liu S, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Daley GQ, Iuliucci J, Dalgarno DC, Clackson T, Sawyer TK, Shakespeare WC..  (2009)  9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation..  J Med Chem,  52  (15): (4743-4756).  [PMID:19572547] [10.1021/jm900166t]
121. Gopalsamy A, Ciszewski G, Hu Y, Lee F, Feldberg L, Frommer E, Kim S, Collins K, Wojciechowicz D, Mallon R..  (2009)  Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors..  Bioorg Med Chem Lett,  19  (10): (2735-2738).  [PMID:19362830] [10.1016/j.bmcl.2009.03.129]
122. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH..  (2009)  Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor..  Bioorg Med Chem Lett,  19  (16): (4720-4723).  [PMID:19596575] [10.1016/j.bmcl.2009.06.066]
123. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS..  (2009)  Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer..  J Med Chem,  52  (21): (6880-6888).  [PMID:19888761] [10.1021/jm901146p]
124. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM..  (2009)  Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles..  Bioorg Med Chem Lett,  19  (22): (6293-6297).  [PMID:19822424] [10.1016/j.bmcl.2009.09.094]
125. Antczak C, Veach DR, Ramirez CN, Minchenko MA, Shum D, Calder PA, Frattini MG, Clarkson B, Djaballah H..  (2009)  Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors..  Bioorg Med Chem Lett,  19  (24): (6872-6876).  [PMID:19889540] [10.1016/j.bmcl.2009.10.085]
126. Shomin CD, Meyer SC, Ghosh I..  (2009)  Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling..  Bioorg Med Chem,  17  (17): (6196-6202).  [PMID:19674907] [10.1016/j.bmc.2009.07.056]
127. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML..  (2009)  Synthesis and evaluation of functionalized isoindigos as antiproliferative agents..  Bioorg Med Chem,  17  (21): (7562-7571).  [PMID:19783149] [10.1016/j.bmc.2009.09.008]
128. Ravindranathan KP, Mandiyan V, Ekkati AR, Bae JH, Schlessinger J, Jorgensen WL..  (2010)  Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening..  J Med Chem,  53  (4): (1662-1672).  [PMID:20121196] [10.1021/jm901386e]
129. Liu X, Xie H, Luo C, Tong L, Wang Y, Peng T, Ding J, Jiang H, Li H..  (2010)  Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening..  J Med Chem,  53  (6): (2661-2665).  [PMID:20178321] [10.1021/jm901798e]
130. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors..  Bioorg Med Chem Lett,  19  (21): (6122-6126).  [PMID:19783434] [10.1016/j.bmcl.2009.09.010]
131. Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T..  (2010)  Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2..  Bioorg Med Chem Lett,  20  (6): (1985-1989).  [PMID:20167481] [10.1016/j.bmcl.2010.01.114]
132. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM..  (2010)  1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors..  Bioorg Med Chem Lett,  20  (12): (3805-3808).  [PMID:20466542] [10.1016/j.bmcl.2010.04.039]
133. Deng X, Lim SM, Zhang J, Gray NS..  (2010)  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl..  Bioorg Med Chem Lett,  20  (14): (4196-4200).  [PMID:20541934] [10.1016/j.bmcl.2010.05.043]
134. Steiner L, Blum G, Friedmann Y, Levitzki A..  (2007)  ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents..  Eur J Pharmacol,  562  (1): (1-11).  [PMID:17376430] [10.1016/j.ejphar.2007.01.052]
135. Verones V, Flouquet N, Farce A, Carato P, Leonce S, Pfeiffer B, Berthelot P, Lebegue N..  (2010)  Synthesis, biological evaluation and docking studies of 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives..  Eur J Med Chem,  45  (12): (5678-5684).  [PMID:20884092] [10.1016/j.ejmech.2010.09.022]
136. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM..  (2011)  Potent and selective thiophene urea-templated inhibitors of S6K..  Bioorg Med Chem Lett,  21  (2): (849-852).  [PMID:21185721] [10.1016/j.bmcl.2010.11.069]
137. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I..  (2011)  Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration..  Bioorg Med Chem Lett,  21  (1): (315-319).  [PMID:21112785] [10.1016/j.bmcl.2010.11.010]
138. Kumar A, Ahmad I, Chhikara BS, Tiwari R, Mandal D, Parang K..  (2011)  Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities..  Bioorg Med Chem Lett,  21  (5): (1342-1346).  [PMID:21300544] [10.1016/j.bmcl.2011.01.047]
139. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM..  (2011)  Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells..  Bioorg Med Chem,  19  (6): (1915-1923).  [PMID:21353571] [10.1016/j.bmc.2011.01.067]
140. Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu D, Pan J, Pei D, Ding K, Ding K..  (2010)  Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway..  ACS Med Chem Lett,  1  (9): (454-459).  [PMID:24900231] [10.1021/ml100146z]
141. Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G, Hittinger A, Ruf S, Strobel H, Nair A, Ritter K, Malleron JL, Dagallier A, El-Ahmad Y, Guilloteau JP, Guizani H, Bouchard H, Venot C..  (2011)  Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors..  Bioorg Med Chem Lett,  21  (8): (2224-2228).  [PMID:21441024] [10.1016/j.bmcl.2011.03.003]
142. Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RM, Tanner AJ, Brown K, Curnock AP, Jimenez JM..  (2011)  Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors..  J Med Chem,  54  (7): (2341-2350).  [PMID:21391610] [10.1021/jm101499u]
143. Okamoto M, Kojima H, Saito N, Okabe T, Masuda Y, Furuya T, Nagano T..  (2011)  Virtual screening and further development of novel ALK inhibitors..  Bioorg Med Chem,  19  (10): (3086-3095).  [PMID:21515061] [10.1016/j.bmc.2011.04.008]
144. Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BG, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CL, White AC, Merritt EA, Van Voorhis WC, Maly DJ..  (2010)  Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii..  ACS Med Chem Lett,  1  (7): (331-335).  [PMID:21116453] [10.1021/ml100096t]
145. Lin WH, Hsieh SY, Yen SC, Chen CT, Yeh TK, Hsu T, Lu CT, Chen CP, Chen CW, Chou LH, Huang YL, Cheng AH, Chang YI, Tseng YJ, Yen KR, Chao YS, Hsu JT, Jiaang WT..  (2011)  Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)..  Bioorg Med Chem,  19  (14): (4173-4182).  [PMID:21708468] [10.1016/j.bmc.2011.06.016]
146. Luan X, Gao C, Zhang N, Chen Y, Sun Q, Tan C, Liu H, Jin Y, Jiang Y..  (2011)  Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors..  Bioorg Med Chem,  19  (11): (3312-3319).  [PMID:21576023] [10.1016/j.bmc.2011.04.053]
147. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P..  (2011)  Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp..  Bioorg Med Chem,  19  (15): (4644-4651).  [PMID:21741249] [10.1016/j.bmc.2011.06.013]
148. Chavez SA, Martinko AJ, Lau C, Pham MN, Cheng K, Bevan DE, Mollnes TE, Yin H..  (2011)  Development of β-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics..  J Med Chem,  54  (13): (4659-4669).  [PMID:21591694] [10.1021/jm2003365]
149. Radi M, Brullo C, Crespan E, Tintori C, Musumeci F, Biava M, Schenone S, Dreassi E, Zamperini C, Maga G, Pagano D, Angelucci A, Bologna M, Botta M..  (2011)  Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells..  Bioorg Med Chem Lett,  21  (19): (5928-5933).  [PMID:21856155] [10.1016/j.bmcl.2011.07.079]
150. Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO..  (2011)  Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis..  J Med Chem,  54  (20): (7193-7205).  [PMID:21851064] [10.1021/jm200782y]
151. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F..  (2011)  1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase..  J Med Chem,  54  (22): (7899-7910).  [PMID:21999461] [10.1021/jm200975u]
152. Kim H, Kim M, Lee J, Yu H, Hah JM..  (2011)  Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells..  Bioorg Med Chem,  19  (22): (6760-6767).  [PMID:22014755] [10.1016/j.bmc.2011.09.042]
153. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K..  (2011)  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold..  J Med Chem,  54  (23): (8030-8050).  [PMID:22003817] [10.1021/jm2008634]
154. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA..  (2012)  Novel and selective spiroindoline-based inhibitors of Sky kinase..  Bioorg Med Chem Lett,  22  (1): (190-193).  [PMID:22119469] [10.1016/j.bmcl.2011.11.036]
155. Rao VK, Chhikara BS, Tiwari R, Shirazi AN, Parang K, Kumar A..  (2012)  One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities..  Bioorg Med Chem Lett,  22  (1): (410-414).  [PMID:22119472] [10.1016/j.bmcl.2011.10.124]
156. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA..  (2012)  Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases..  Eur J Med Chem,  48  (143-152).  [PMID:22204902] [10.1016/j.ejmech.2011.12.006]
157. Heidary DK, Huang G, Boucher D, Ma J, Forster C, Grey R, Xu J, Arnost M, Choquette D, Chen G, Zhou JH, Yao YM, Ball ED, Namchuk M, Davies RJ, Henkel G..  (2012)  VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia..  J Med Chem,  55  (2): (725-734).  [PMID:22221201] [10.1021/jm201198w]
158. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM..  (2012)  Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors..  Bioorg Med Chem Lett,  22  (5): (2015-2019).  [PMID:22335895] [10.1016/j.bmcl.2012.01.028]
159. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS..  (2012)  Characterization of TAE684 as a potent LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (5): (1864-1869).  [PMID:22335897] [10.1016/j.bmcl.2012.01.084]
160. Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Jordan AD, Masucci JA, Jones WJ, Abad MC, Gibbs AC, Petrounia I..  (2011)  Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site..  ACS Med Chem Lett,  2  (7): (538-543).  [PMID:24900346] [10.1021/ml200070g]
161. Larson ET, Ojo KK, Murphy RC, Johnson SM, Zhang Z, Kim JE, Leibly DJ, Fox AM, Reid MC, Dale EJ, Perera BG, Kim J, Hewitt SN, Hol WG, Verlinde CL, Fan E, Van Voorhis WC, Maly DJ, Merritt EA..  (2012)  Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1..  J Med Chem,  55  (6): (2803-2810).  [PMID:22369268] [10.1021/jm201725v]
162. Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, Fry AM, Hoelder S..  (2012)  Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity..  J Med Chem,  55  (7): (3228-3241).  [PMID:22404346] [10.1021/jm201683b]
163. Zhang Z, Ojo KK, Johnson SM, Larson ET, He P, Geiger JA, Castellanos-Gonzalez A, White AC, Parsons M, Merritt EA, Maly DJ, Verlinde CL, Van Voorhis WC, Fan E..  (2012)  Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1..  Bioorg Med Chem Lett,  22  (16): (5264-5267).  [PMID:22795629] [10.1016/j.bmcl.2012.06.050]
164. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B..  (2012)  Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α..  J Med Chem,  55  (9): (4407-4424).  [PMID:22533818] [10.1021/jm300309a]
165. Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Gibbs AC, Connelly MA..  (2012)  Pyrimidinopyrimidine inhibitors of ketohexokinase: exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket..  Bioorg Med Chem Lett,  22  (16): (5326-5329).  [PMID:22795331] [10.1016/j.bmcl.2012.06.008]
166. Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BG, Dale EJ, He P, Reid MC, Fox AM, Mueller NR, Merritt EA, Fan E, Parsons M, Van Voorhis WC, Maly DJ..  (2012)  Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity..  J Med Chem,  55  (5): (2416-2426).  [PMID:22320388] [10.1021/jm201713h]
167. Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O..  (2012)  Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors..  J Med Chem,  55  (11): (5467-5482).  [PMID:22548342] [10.1021/jm300403a]
168. Illig CR, Manthey CL, Wall MJ, Meegalla SK, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE..  (2011)  Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141)..  J Med Chem,  54  (22): (7860-7883).  [PMID:22039836] [10.1021/jm200900q]
169. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N..  (2012)  Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease..  Bioorg Med Chem Lett,  22  (14): (4613-4618).  [PMID:22726925] [10.1016/j.bmcl.2012.05.090]
170. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS..  (2012)  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (17): (5625-5629).  [PMID:22863203] [10.1016/j.bmcl.2012.06.104]
171. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B..  (2012)  Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3..  Bioorg Med Chem Lett,  22  (24): (7634-7640).  [PMID:23107479] [10.1016/j.bmcl.2012.10.016]
172. Lafleur K, Dong J, Huang D, Caflisch A, Nevado C..  (2013)  Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography..  J Med Chem,  56  (1): (84-96).  [PMID:23253074] [10.1021/jm301187e]
173. Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V..  (2013)  Synthesis and biological evaluation of guanidino analogues of roscovitine..  Eur J Med Chem,  62  (443-452).  [PMID:23399722] [10.1016/j.ejmech.2013.01.021]
174. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S..  (2013)  Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase..  Bioorg Med Chem Lett,  23  (6): (1588-1591).  [PMID:23414803] [10.1016/j.bmcl.2013.01.110]
175. Zhang M, Zhu W, Ding N, Zhang W, Li Y..  (2013)  Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening..  Bioorg Med Chem Lett,  23  (7): (2225-2229).  [PMID:23434226] [10.1016/j.bmcl.2013.01.056]
176. Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, Taylor D, Clough B, Green JL, Holder AA..  (2013)  Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1)..  Bioorg Med Chem Lett,  23  (10): (3064-3069).  [PMID:23570789] [10.1016/j.bmcl.2013.03.017]
177. Nasrolahi Shirazi A, Tiwari RK, Brown A, Mandal D, Sun G, Parang K..  (2013)  Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors..  Bioorg Med Chem Lett,  23  (11): (3230-3234).  [PMID:23602444] [10.1016/j.bmcl.2013.03.124]
178. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT..  (2013)  Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)..  Bioorg Med Chem,  21  (11): (2856-2867).  [PMID:23618709] [10.1016/j.bmc.2013.03.083]
179. Pauwels D, Klaassen H, Lahortiga I, Kilonda A, Jacobs K, Sweron B, Corbau R, Chaltin P, Marchand A, Cools J..  (2013)  Identification of novel FLT3 kinase inhibitors..  Eur J Med Chem,  63  (713-721).  [PMID:23567961] [10.1016/j.ejmech.2013.03.024]
180. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M..  (2013)  Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors..  Bioorg Med Chem Lett,  23  (9): (2743-2749).  [PMID:23522834] [10.1016/j.bmcl.2013.02.065]
181. Ko KS, Steffey ME, Brandvold KR, Soellner MB..  (2013)  Development of a chimeric c-Src kinase and HDAC inhibitor..  ACS Med Chem Lett,  4  (8): (779-783).  [PMID:24015327] [10.1021/ml400175d]
182. Alder CM, Ambler M, Campbell AJ, Champigny AC, Deakin AM, Harling JD, Harris CA, Longstaff T, Lynn S, Maxwell AC, Mooney CJ, Scullion C, Singh OM, Smith IE, Somers DO, Tame CJ, Wayne G, Wilson C, Woolven JM..  (2013)  Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy..  ACS Med Chem Lett,  4  (10): (948-952).  [PMID:24900590] [10.1021/ml400206q]
183. Huang H, Guzman-Perez A, Acquaviva L, Berry V, Bregman H, Dovey J, Gunaydin H, Huang X, Huang L, Saffran D, Serafino R, Schneider S, Wilson C, DiMauro EF..  (2013)  Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitors..  ACS Med Chem Lett,  4  (12): (1218-1223).  [PMID:24900633] [10.1021/ml4003315]
184. Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, Kaplan DR, Griffin C, Aman AM, Al-Awar R, Weiss S, Gunning PT..  (2013)  Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma..  ACS Med Chem Lett,  4  (11): (1102-1107).  [PMID:24900612] [10.1021/ml4003138]
185. Zhang Z, Ojo KK, Vidadala R, Huang W, Geiger JA, Scheele S, Choi R, Reid MC, Keyloun KR, Rivas K, Siddaramaiah LK, Comess KM, Robinson KP, Merta PJ, Kifle L, Hol WG, Parsons M, Merritt EA, Maly DJ, Verlinde CL, Van Voorhis WC, Fan E..  (2014)  Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold..  ACS Med Chem Lett,  5  (1): (40-44).  [PMID:24494061] [10.1021/ml400315s]
186. Chen H, Guan Y, Yuan G, Zhang Q, Jing N..  (2014)  A perylene derivative regulates HIF-1α and Stat3 signaling pathways..  Bioorg Med Chem,  22  (4): (1496-1505).  [PMID:24485121] [10.1016/j.bmc.2013.10.018]
187. Temburnikar KW, Zimmermann SC, Kim NT, Ross CR, Gelbmann C, Salomon CE, Wilson GM, Balzarini J, Seley-Radtke KL..  (2014)  Antiproliferative activities of halogenated thieno[3,2-d]pyrimidines..  Bioorg Med Chem,  22  (7): (2113-2122).  [PMID:24631358] [10.1016/j.bmc.2014.02.033]
188. Shi Q, Tebben A, Dyckman AJ, Li H, Liu C, Lin J, Spergel S, Burke JR, McIntyre KW, Olini GC, Strnad J, Surti N, Muckelbauer JK, Chang C, An Y, Cheng L, Ruan Q, Leftheris K, Carter PH, Tino J, De Lucca GV..  (2014)  Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases..  Bioorg Med Chem Lett,  24  (9): (2206-2211).  [PMID:24685542] [10.1016/j.bmcl.2014.02.075]
189. Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG..  (2014)  Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction..  Eur J Med Chem,  80  (154-166).  [PMID:24780592] [10.1016/j.ejmech.2014.04.041]
190. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB..  (2014)  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2..  Bioorg Med Chem Lett,  24  (12): (2635-2639).  [PMID:24813737] [10.1016/j.bmcl.2014.04.068]
191. Shim HJ, Yang HR, Kim HIe, Kang SA, No KT, Jung YH, Lee ST..  (2014)  Discovery of (E)-5-(benzylideneamino)-1H-benzo[d]imidazol-2(3H)-one derivatives as inhibitors for PTK6..  Bioorg Med Chem Lett,  24  (19): (4659-4663).  [PMID:25205190] [10.1016/j.bmcl.2014.08.036]
192. Zhang P, Li S, Gao Y, Lu W, Huang K, Ye D, Li X, Chu Y..  (2014)  Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake..  Bioorg Med Chem Lett,  24  (24): (5639-5643).  [PMID:25467150] [10.1016/j.bmcl.2014.10.078]
193. Xu Y, Brenning BG, Kultgen SG, Foulks JM, Clifford A, Lai S, Chan A, Merx S, McCullar MV, Kanner SB, Ho KK..  (2015)  Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors..  ACS Med Chem Lett,  6  (1): (63-67).  [PMID:25589932] [10.1021/ml500300c]
194. Song Z, Yang Y, Liu Z, Peng X, Guo J, Yang X, Wu K, Ai J, Ding J, Geng M, Zhang A..  (2015)  Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases..  J Med Chem,  58  (1): (197-211).  [PMID:24785465] [10.1021/jm5005144]
195. Sandhu S, Bansal Y, Silakari O, Bansal G..  (2014)  Coumarin hybrids as novel therapeutic agents..  Bioorg Med Chem,  22  (15): (3806-3814).  [PMID:24934993] [10.1016/j.bmc.2014.05.032]
196. Park BS, Al-Sanea MM, Abdelazem AZ, Park HM, Roh EJ, Park HM, Yoo KH, Sim T, Tae JS, Lee SH..  (2014)  Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors..  Bioorg Med Chem,  22  (15): (3871-3878).  [PMID:24997577] [10.1016/j.bmc.2014.06.020]
197. Horbert R, Pinchuk B, Johannes E, Schlosser J, Schmidt D, Cappel D, Totzke F, Schächtele C, Peifer C..  (2015)  Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics..  J Med Chem,  58  (1): (170-182).  [PMID:25007344] [10.1021/jm500373x]
198. Unzue A, Dong J, Lafleur K, Zhao H, Frugier E, Caflisch A, Nevado C..  (2014)  Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validation..  J Med Chem,  57  (15): (6834-6844).  [PMID:25076195] [10.1021/jm5009242]
199. Tintori C, Fallacara AL, Radi M, Zamperini C, Dreassi E, Crespan E, Maga G, Schenone S, Musumeci F, Brullo C, Richters A, Gasparrini F, Angelucci A, Festuccia C, Delle Monache S, Rauh D, Botta M..  (2015)  Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma..  J Med Chem,  58  (1): (347-361).  [PMID:25469771] [10.1021/jm5013159]
200. Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA..  (2015)  Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases..  J Med Chem,  58  (1): (443-456).  [PMID:25475894] [10.1021/jm501557a]
201. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ..  (2015)  Development of novel ACK1/TNK2 inhibitors using a fragment-based approach..  J Med Chem,  58  (6): (2746-2763).  [PMID:25699576] [10.1021/jm501929n]
202. Meyer C, Hoeger B, Chatterjee J, Köhn M..  (2015)  Azide-alkyne cycloaddition-mediated cyclization of phosphonopeptides and their evaluation as PTP1B binders and enrichment tools..  Bioorg Med Chem,  23  (12): (2848-2853).  [PMID:25805211] [10.1016/j.bmc.2015.03.015]
203. Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY..  (2015)  Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer..  J Med Chem,  58  (9): (3957-3974).  [PMID:25835317] [10.1021/acs.jmedchem.5b00270]
204. Tintori C, La Sala G, Vignaroli G, Botta L, Fallacara AL, Falchi F, Radi M, Zamperini C, Dreassi E, Dello Iacono L, Orioli D, Biamonti G, Garbelli M, Lossani A, Gasparrini F, Tuccinardi T, Laurenzana I, Angelucci A, Maga G, Schenone S, Brullo C, Musumeci F, Desogus A, Crespan E, Botta M..  (2015)  Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors..  J Med Chem,  58  (11): (4590-4609).  [PMID:25923950] [10.1021/acs.jmedchem.5b00140]
205. Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL..  (2015)  Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells..  J Med Chem,  58  (10): (4165-4179).  [PMID:25965804] [10.1021/acs.jmedchem.5b00067]
206. Choi HS, Rucker PV, Wang Z, Fan Y, Albaugh P, Chopiuk G, Gessier F, Sun F, Adrian F, Liu G, Hood T, Li N, Jia Y, Che J, McCormack S, Li A, Li J, Steffy A, Culazzo A, Tompkins C, Phung V, Kreusch A, Lu M, Hu B, Chaudhary A, Prashad M, Tuntland T, Liu B, Harris J, Seidel HM, Loren J, Molteni V..  (2015)  (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors..  ACS Med Chem Lett,  6  (5): (562-567).  [PMID:26005534] [10.1021/acsmedchemlett.5b00050]
207. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT..  (2015)  Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations..  Eur J Med Chem,  100  (151-161).  [PMID:26081023] [10.1016/j.ejmech.2015.05.008]
208. Engel J, Richters A, Getlik M, Tomassi S, Keul M, Termathe M, Lategahn J, Becker C, Mayer-Wrangowski S, Grütter C, Uhlenbrock N, Krüll J, Schaumann N, Eppmann S, Kibies P, Hoffgaard F, Heil J, Menninger S, Ortiz-Cuaran S, Heuckmann JM, Tinnefeld V, Zahedi RP, Sos ML, Schultz-Fademrecht C, Thomas RK, Kast SM, Rauh D..  (2015)  Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach..  J Med Chem,  58  (17): (6844-6863).  [PMID:26275028] [10.1021/acs.jmedchem.5b01082]
209. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L..  (2015)  Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity..  Bioorg Med Chem,  23  (21): (7000-7006).  [PMID:26455654] [10.1016/j.bmc.2015.09.038]
210. Ravez S, Arsenlis S, Barczyk A, Dupont A, Frédérick R, Hesse S, Kirsch G, Depreux P, Goossens L..  (2015)  Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors..  Bioorg Med Chem,  23  (22): (7340-7347).  [PMID:26526740] [10.1016/j.bmc.2015.10.035]
211. Sestito S, Nesi G, Daniele S, Martelli A, Digiacomo M, Borghini A, Pietra D, Calderone V, Lapucci A, Falasca M, Parrella P, Notarangelo A, Breschi MC, Macchia M, Martini C, Rapposelli S..  (2015)  Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme..  Eur J Med Chem,  105  (274-288).  [PMID:26498573] [10.1016/j.ejmech.2015.10.020]
212. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T..  (2015)  Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent..  Bioorg Med Chem Lett,  25  (24): (5687-5693).  [PMID:26547690] [10.1016/j.bmcl.2015.10.098]
213. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G..  (2016)  Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes..  Bioorg Med Chem Lett,  26  (2): (424-428).  [PMID:26704265] [10.1016/j.bmcl.2015.11.099]
214. Cui Z, Li X, Li L, Zhang B, Gao C, Chen Y, Tan C, Liu H, Xie W, Yang T, Jiang Y..  (2016)  Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment..  Bioorg Med Chem,  24  (2): (261-269).  [PMID:26707846] [10.1016/j.bmc.2015.12.011]
215. Tzou YM, Bailey SK, Yuan K, Shin R, Zhang W, Chen Y, Singh RK, Shevde LA, Krishna NR..  (2016)  Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer..  Bioorg Med Chem Lett,  26  (4): (1237-1244).  [PMID:26803204] [10.1016/j.bmcl.2016.01.027]
216. Aman W, Lee J, Kim M, Yang S, Jung H, Hah JM..  (2016)  Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation..  Bioorg Med Chem Lett,  26  (4): (1188-1192).  [PMID:26810260] [10.1016/j.bmcl.2016.01.037]
217. Huang W, Ojo KK, Zhang Z, Rivas K, Vidadala RS, Scheele S, DeRocher AE, Choi R, Hulverson MA, Barrett LK, Bruzual I, Siddaramaiah LK, Kerchner KM, Kurnick MD, Freiberg GM, Kempf D, Hol WG, Merritt EA, Neckermann G, de Hostos EL, Isoherranen N, Maly DJ, Parsons M, Doggett JS, Van Voorhis WC, Fan E..  (2015)  SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1..  ACS Med Chem Lett,  6  (12): (1184-1189).  [PMID:26693272] [10.1021/acsmedchemlett.5b00319]
218. Huard K, Gosset JR, Montgomery JI, Gilbert A, Hayward MM, Magee TV, Cabral S, Uccello DP, Bahnck K, Brown J, Purkal J, Gorgoglione M, Lanba A, Futatsugi K, Herr M, Genung NE, Aspnes G, Polivkova J, Garcia-Irizarry CN, Li Q, Canterbury D, Niosi M, Vera NB, Li Z, Khunte B, Siderewicz J, Rolph T, Erion DM..  (2016)  Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family..  J Med Chem,  59  (3): (1165-1175).  [PMID:26734723] [10.1021/acs.jmedchem.5b01752]
219. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J..  (2016)  8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors..  J Med Chem,  59  (4): (1388-1409).  [PMID:26741168] [10.1021/acs.jmedchem.5b01635]
220. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J..  (2016)  Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore..  Bioorg Med Chem Lett,  26  (5): (1443-1451).  [PMID:26852363] [10.1016/j.bmcl.2016.01.062]
221. Liang X, Liu X, Wang B, Zou F, Wang A, Qi S, Chen C, Zhao Z, Wang W, Qi Z, Lv F, Hu Z, Wang L, Zhang S, Liu Q, Liu J..  (2016)  Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia..  J Med Chem,  59  (5): (1984-2004).  [PMID:26789553] [10.1021/acs.jmedchem.5b01618]
222. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A..  (2016)  Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors..  J Med Chem,  59  (8): (3886-3905).  [PMID:27010810] [10.1021/acs.jmedchem.6b00087]
223. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J..  (2016)  Identification of quinones as novel PIM1 kinase inhibitors..  Bioorg Med Chem Lett,  26  (13): (3187-3191).  [PMID:27173800] [10.1016/j.bmcl.2016.04.079]
224. Rudolph J, Murray LJ, Ndubaku CO, O'Brien T, Blackwood E, Wang W, Aliagas I, Gazzard L, Crawford JJ, Drobnick J, Lee W, Zhao X, Hoeflich KP, Favor DA, Dong P, Zhang H, Heise CE, Oh A, Ong CC, La H, Chakravarty P, Chan C, Jakubiak D, Epler J, Ramaswamy S, Vega R, Cain G, Diaz D, Zhong Y..  (2016)  Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window..  J Med Chem,  59  (11): (5520-5541).  [PMID:27167326] [10.1021/acs.jmedchem.6b00638]
225. Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW..  (2016)  Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK..  Bioorg Med Chem Lett,  26  (15): (3562-3566).  [PMID:27335255] [10.1016/j.bmcl.2016.06.021]
226. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA..  (2016)  A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties..  Bioorg Med Chem Lett,  26  (15): (3457-3463).  [PMID:27363938] [10.1016/j.bmcl.2016.06.046]
227. Huang W, Hulverson MA, Zhang Z, Choi R, Hart KJ, Kennedy M, Vidadala RSR, Maly DJ, Van Voorhis WC, Lindner SE, Fan E, Ojo KK..  (2016)  5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents..  Bioorg Med Chem Lett,  26  (22): (5487-5491).  [PMID:27780638] [10.1016/j.bmcl.2016.10.014]
228. El-Moghazy SM, George RF, Osman EEA, Elbatrawy AA, Kissova M, Colombo A, Crespan E, Maga G..  (2016)  Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line..  Eur J Med Chem,  123  (1-13).  [PMID:27474918] [10.1016/j.ejmech.2016.07.034]
229. Li S, Zhang W, Yang Y, Ma T, Guo J, Wang S, Yu W, Kong L..  (2016)  Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein..  Eur J Med Chem,  124  (1006-1018).  [PMID:27783972] [10.1016/j.ejmech.2016.10.028]
230. Klaeger S, Heinzlmeir S and Wilhelm M et al.  (2017)  The target landscape of clinical kinase drugs..  Science,  358  (6367):   [PMID:29191878] [10.1126/science.aan4368]
231. Musumeci F, Fallacara AL, Brullo C, Grossi G, Botta L, Calandro P, Chiariello M, Kissova M, Crespan E, Maga G, Schenone S..  (2017)  Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma..  Eur J Med Chem,  127  (369-378).  [PMID:28076826] [10.1016/j.ejmech.2016.12.036]
232. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G..  (2017)  Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells..  Eur J Med Chem,  127  (997-1011).  [PMID:27839788] [10.1016/j.ejmech.2016.11.009]
233. Tassini S, Sun L, Lanko K, Crespan E, Langron E, Falchi F, Kissova M, Armijos-Rivera JI, Delang L, Mirabelli C, Neyts J, Pieroni M, Cavalli A, Costantino G, Maga G, Vergani P, Leyssen P, Radi M..  (2017)  Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases..  J Med Chem,  60  (4): (1400-1416).  [PMID:28122178] [10.1021/acs.jmedchem.6b01521]
234. Argyros O, Lougiakis N, Kouvari E, Papafotika A, Raptopoulou CP, Psycharis V, Christoforidis S, Pouli N, Marakos P, Tamvakopoulos C..  (2017)  Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity..  Eur J Med Chem,  126  (954-968).  [PMID:28006668] [10.1016/j.ejmech.2016.12.025]
235. Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR..  (2017)  A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore..  Bioorg Med Chem Lett,  27  (3): (406-412).  [PMID:28049589] [10.1016/j.bmcl.2016.12.056]
236. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H..  (2017)  Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer..  J Med Chem,  60  (14): (6018-6035).  [PMID:28714692] [10.1021/acs.jmedchem.7b00076]
237. Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ..  (2017)  Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization..  Eur J Med Chem,  134  (147-158).  [PMID:28411455] [10.1016/j.ejmech.2017.03.085]
238. Rutaganira FU, Barks J, Dhason MS, Wang Q, Lopez MS, Long S, Radke JB, Jones NG, Maddirala AR, Janetka JW, El Bakkouri M, Hui R, Shokat KM, Sibley LD..  (2017)  Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii..  J Med Chem,  60  (24): (9976-9989).  [PMID:28933846] [10.1021/acs.jmedchem.7b01192]
239. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y..  (2018)  Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines..  J Med Chem,  61  (1): (140-157).  [PMID:29189002] [10.1021/acs.jmedchem.7b01091]
240. Gaboriaud-Kolar N, Myrianthopoulos V, Vougogiannopoulou K, Gerolymatos P, Horne DA, Jove R, Mikros E, Nam S, Skaltsounis AL..  (2016)  Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines..  J Nat Prod,  79  (10): (2464-2471).  [PMID:27726390] [10.1021/acs.jnatprod.6b00285]
241. Smith GP, Badolo L, Chell V, Chen IJ, Christensen KV, David L, Daechsel JA, Hentzer M, Herzig MC, Mikkelsen GK, Watson SP, Williamson DS..  (2017)  The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors..  Bioorg Med Chem Lett,  27  (18): (4500-4505).  [PMID:28802631] [10.1016/j.bmcl.2017.07.072]
242. Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, Lei M, Cheng H, Feng H, Shi J, Wang J, Zhang Z, Jin T, Chen S, Hu S, Zhu Y..  (2017)  Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants..  Eur J Med Chem,  135  (12-23).  [PMID:28426996] [10.1016/j.ejmech.2017.04.036]
243. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS79182026: A potent orally active hepcidin production inhibitor..  Bioorg Med Chem Lett,  27  (16): (3716-3722).  [PMID:28705644] [10.1016/j.bmcl.2017.07.004]
244. Boga SB, Alhassan AB, Liu J, Guiadeen D, Krikorian A, Gao X, Wang J, Yu Y, Anand R, Liu S, Yang C, Wu H, Cai J, Zhu H, Desai J, Maloney K, Gao YD, Fischmann TO, Presland J, Mansueto M, Xu Z, Leccese E, Knemeyer I, Garlisi CG, Bays N, Stivers P, Brandish PE, Hicks A, Cooper A, Kim RM, Kozlowski JA..  (2017)  Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis..  Bioorg Med Chem Lett,  27  (16): (3939-3943).  [PMID:28720503] [10.1016/j.bmcl.2017.03.040]
245. He L, Li D, Zhang C, Bai P, Chen L..  (2017)  Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC..  Bioorg Med Chem Lett,  27  (17): (4171-4175).  [PMID:28734581] [10.1016/j.bmcl.2017.07.009]
246. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives..  Bioorg Med Chem Lett,  27  (23): (5252-5257).  [PMID:29079471] [10.1016/j.bmcl.2017.10.031]
247. Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T..  (2018)  Identification and biological evaluation of thiazole-based inverse agonists of RORγt..  Bioorg Med Chem Lett,  28  (9): (1446-1455).  [PMID:29631962] [10.1016/j.bmcl.2018.03.093]
248. Wang T, Bemis G, Hanzelka B, Zuccola H, Wynn M, Moody CS, Green J, Locher C, Liu A, Gao H, Xu Y, Wang S, Wang J, Bennani YL, Thomson JA, Müh U..  (2017)  Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions..  ACS Med Chem Lett,  8  (12): (1224-1229).  [PMID:29259738] [10.1021/acsmedchemlett.7b00239]
249. Cui Z, Chen S, Wang Y, Gao C, Chen Y, Tan C, Jiang Y..  (2017)  Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment..  Eur J Med Chem,  136  (372-381).  [PMID:28525838] [10.1016/j.ejmech.2017.05.006]
250. Farag AK, Elkamhawy A, Londhe AM, Lee KT, Pae AN, Roh EJ..  (2017)  Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders..  Eur J Med Chem,  141  (657-675).  [PMID:29107425] [10.1016/j.ejmech.2017.10.003]
251. Guo J, Yu W, Cai G, Zhang W, Li S, Zhu J, Song D, Kong L..  (2018)  Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors..  Eur J Med Chem,  151  (752-764).  [PMID:29674294] [10.1016/j.ejmech.2018.03.053]
252. Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, Abd Elmageed ZY, Ali HI..  (2018)  Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition..  Eur J Med Chem,  152  (31-52).  [PMID:29684708] [10.1016/j.ejmech.2018.04.029]
253. Reiersølmoen AC, Han J, Sundby E, Hoff BH..  (2018)  Identification of fused pyrimidines as interleukin 17 secretion inhibitors..  Eur J Med Chem,  155  (562-578).  [PMID:29909341] [10.1016/j.ejmech.2018.06.019]
254. Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA..  (2017)  Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis..  Bioorg Med Chem Lett,  27  (8): (1867-1873).  [PMID:28279528] [10.1016/j.bmcl.2017.02.026]
255. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W..  (2018)  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer..  Bioorg Med Chem,  26  (3): (590-602).  [PMID:29289448] [10.1016/j.bmc.2017.12.020]
256. Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A..  (2018)  Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening..  J Med Chem,  61  (5): (2104-2110).  [PMID:29466002] [10.1021/acs.jmedchem.7b01605]
257. Zhang L, Shi L, Soars SM, Kamps J, Yin H..  (2018)  Discovery of Novel Small-Molecule Inhibitors of NF-κB Signaling with Antiinflammatory and Anticancer Properties..  J Med Chem,  61  (14): (5881-5899).  [PMID:29870245] [10.1021/acs.jmedchem.7b01557]
258. Cho H, Shin I, Ju E, Choi S, Hur W, Kim H, Hong E, Kim ND, Choi HG, Gray NS, Sim T..  (2018)  First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia..  J Med Chem,  61  (18): (8353-8373).  [PMID:30153003] [10.1021/acs.jmedchem.8b00882]
259. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C..  (2018)  Effects of rigidity on the selectivity of protein kinase inhibitors..  Eur J Med Chem,  146  (519-528).  [PMID:29407977] [10.1016/j.ejmech.2018.01.053]
260. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J..  (2018)  Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia..  Eur J Med Chem,  150  (366-384).  [PMID:29544149] [10.1016/j.ejmech.2018.03.003]
261. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L..  (2018)  Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors..  Eur J Med Chem,  150  (491-505).  [PMID:29549836] [10.1016/j.ejmech.2018.02.080]
262. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG..  (2018)  Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells..  Bioorg Med Chem,  26  (14): (3899-3908).  [PMID:29921474] [10.1016/j.bmc.2018.06.010]
263. Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW..  (2018)  Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors..  Eur J Med Chem,  145  (606-621).  [PMID:29348070] [10.1016/j.ejmech.2017.12.041]
264. Lopez-Tapia F, Brotherton-Pleiss C, Yue P, Murakami H, Costa Araujo AC, Reis Dos Santos B, Ichinotsubo E, Rabkin A, Shah R, Lantz M, Chen S, Tius MA, Turkson J..  (2018)  Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors..  ACS Med Chem Lett,  9  (3): (250-255).  [PMID:29541369] [10.1021/acsmedchemlett.7b00544]
265. Gao JB, Yang SJ, Yan ZR, Zhang XJ, Pu DB, Wang LX, Li XL, Zhang RH, Xiao WL..  (2018)  Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors..  J Nat Prod,  81  (4): (998-1006).  [PMID:29578342] [10.1021/acs.jnatprod.7b01082]
266. Fearon D, Westwood IM, van Montfort RLM, Bayliss R, Jones K, Bavetsias V..  (2018)  Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition..  Bioorg Med Chem,  26  (11): (3021-3029).  [PMID:29764757] [10.1016/j.bmc.2018.04.033]
267. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W..  (2018)  Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors..  Bioorg Med Chem Lett,  28  (20): (3356-3362).  [PMID:30227946] [10.1016/j.bmcl.2018.09.006]
268. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q..  (2018)  Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor..  Eur J Med Chem,  158  (896-916).  [PMID:30253346] [10.1016/j.ejmech.2018.09.025]
269. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F..  (2018)  Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer..  Eur J Med Chem,  157  (1300-1325).  [PMID:30195240] [10.1016/j.ejmech.2018.08.031]
270. Molinari A, Fallacara AL, Di Maria S, Zamperini C, Poggialini F, Musumeci F, Schenone S, Angelucci A, Colapietro A, Crespan E, Kissova M, Maga G, Botta M..  (2018)  Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment..  Bioorg Med Chem Lett,  28  (21): (3454-3457).  [PMID:30262428] [10.1016/j.bmcl.2018.09.024]
271. Haile PA, Casillas LN, Bury MJ, Mehlmann JF, Singhaus R, Charnley AK, Hughes TV, DeMartino MP, Wang GZ, Romano JJ, Dong X, Plotnikov NV, Lakdawala AS, Convery MA, Votta BJ, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, LePage C, Ouellette MT, Totoritis RD, Donovan BT, Brown BS, Chaudhary KW, Gough PJ, Bertin J, Marquis RW..  (2018)  Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel..  ACS Med Chem Lett,  9  (10): (1039-1044).  [PMID:30344914] [10.1021/acsmedchemlett.8b00344]
272. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M..  (2019)  Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis..  ACS Med Chem Lett,  10  (9): (1272-1278).  [PMID:31531196] [10.1021/acsmedchemlett.9b00142]
273. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L..  (2019)  Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer..  Eur J Med Chem,  184  (111728-111728).  [PMID:31610375] [10.1016/j.ejmech.2019.111728]
274. Baska F, Sipos A, Őrfi Z, Nemes Z, Dobos J, Szántai-Kis C, Szabó E, Szénási G, Dézsi L, Hamar P, Cserepes MT, Tóvári J, Garamvölgyi R, Krekó M, Őrfi L..  (2019)  Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases..  Eur J Med Chem,  184  (111710-111710).  [PMID:31614258] [10.1016/j.ejmech.2019.111710]
275. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK..  (2019)  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells..  Eur J Med Chem,  161  (456-467).  [PMID:30384048] [10.1016/j.ejmech.2018.10.052]
276. Osborne J, Birchall K, Tsagris DJ, Lewis SJ, Smiljanic-Hurley E, Taylor DL, Levy A, Alessi DR, McIver EG..  (2019)  Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1..  Bioorg Med Chem Lett,  29  (4): (668-673).  [PMID:30554956] [10.1016/j.bmcl.2018.11.058]
277. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z..  (2019)  Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia..  Eur J Med Chem,  171  (221-234).  [PMID:30925338] [10.1016/j.ejmech.2019.03.039]
278. Martínez-González S, Rodríguez-Arístegui S, Gómez de la Oliva CA, Hernández AI, González Cantalapiedra E, Varela C, García AB, Rabal O, Oyarzabal J, Bischoff JR, Klett J, Albarrán MI, Cebriá A, Ajenjo N, García-Serelde B, Gómez-Casero E, Cuadrado-Urbano M, Cebrián D, Blanco-Aparicio C, Pastor J..  (2019)  Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors..  Eur J Med Chem,  168  (87-109).  [PMID:30802730] [10.1016/j.ejmech.2019.02.022]
279. Li W, Chu J, Fan T, Zhang W, Yao M, Ning Z, Wang M, Sun J, Zhao X, Wen A..  (2019)  Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway..  Bioorg Med Chem Lett,  29  (14): (1831-1835).  [PMID:31097376] [10.1016/j.bmcl.2019.05.005]
280. Zhang C, Pei H, He J, Zhu J, Li W, Niu T, Xiang M, Chen L..  (2019)  Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis..  Eur J Med Chem,  169  (121-143).  [PMID:30875504] [10.1016/j.ejmech.2019.02.077]
281. Liang X, Zang J, Li X, Tang S, Huang M, Geng M, Chou CJ, Li C, Cao Y, Xu W, Liu H, Zhang Y..  (2019)  Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies..  J Med Chem,  62  (8): (3898-3923).  [PMID:30901208] [10.1021/acs.jmedchem.8b01597]
282. Abdelaziz AM, Basnet SKC, Islam S, Li M, Tadesse S, Albrecht H, Gerber C, Yu M, Wang S..  (2019)  Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors..  Bioorg Med Chem Lett,  29  (18): (2650-2654).  [PMID:31362920] [10.1016/j.bmcl.2019.07.043]
283. Heng H, Wang Z, Li H, Huang Y, Lan Q, Guo X, Zhang L, Zhi Y, Cai J, Qin T, Xiang L, Wang S, Chen Y, Lu T, Lu S..  (2019)  Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model..  Eur J Med Chem,  176  (248-267).  [PMID:31103903] [10.1016/j.ejmech.2019.05.021]
284. Huang MR, Hsu YL, Lin TC, Cheng TJ, Li LW, Tseng YW, Chou YS, Liu JH, Pan SH, Fang JM, Wong CH..  (2019)  Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer..  Eur J Med Chem,  181  (111551-111551).  [PMID:31376567] [10.1016/j.ejmech.2019.07.054]
285. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R..  (2019)  Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer..  Eur J Med Chem,  181  (111535-111535).  [PMID:31376566] [10.1016/j.ejmech.2019.07.038]
286. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S..  (2019)  Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models..  J Med Chem,  62  (23): (10691-10710).  [PMID:31693351] [10.1021/acs.jmedchem.9b01143]
287. Lin WH, Wu SY, Yeh TK, Chen CT, Song JS, Shiao HY, Kuo CC, Hsu T, Lu CT, Wang PC, Wu TS, Peng YH, Lin HY, Chen CP, Weng YL, Kung FC, Wu MH, Su YC, Huang KW, Chou LH, Hsueh CC, Yen KJ, Kuo PC, Huang CL, Chen LT, Shih C, Tsai HJ, Jiaang WT..  (2019)  Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia..  J Med Chem,  62  (24): (11135-11150).  [PMID:31721578] [10.1021/acs.jmedchem.9b01229]
288. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS..  (2017)  Discovery of a potent dual ALK and EGFR T790M inhibitor..  Eur J Med Chem,  136  (497-510).  [PMID:28528303] [10.1016/j.ejmech.2017.04.079]
289. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W..  (2018)  Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors..  J Med Chem,  61  (20): (9085-9104).  [PMID:29522671] [10.1021/acs.jmedchem.7b01843]
290. Farag AK, Hassan AHE, Jeong H, Kwon Y, Choi JG, Oh MS, Park KD, Kim YK, Roh EJ..  (2019)  First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent..  Eur J Med Chem,  162  (161-175).  [PMID:30445265] [10.1016/j.ejmech.2018.10.057]
291. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY..  (2019)  Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3..  Eur J Med Chem,  168  (58-77).  [PMID:30798053] [10.1016/j.ejmech.2018.12.063]
292. Cai G, Yu W, Song D, Zhang W, Guo J, Zhu J, Ren Y, Kong L..  (2019)  Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors..  Eur J Med Chem,  174  (236-251).  [PMID:31048139] [10.1016/j.ejmech.2019.04.024]
293. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P..  (2019)  Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors..  Eur J Med Chem,  175  (309-329).  [PMID:31096153] [10.1016/j.ejmech.2019.04.035]
294. Andrews LD, Kane TR, Dozzo P, Haglund CM, Hilderbrandt DJ, Linsell MS, Machajewski T, McEnroe G, Serio AW, Wlasichuk KB, Neau DB, Pakhomova S, Waldrop GL, Sharp M, Pogliano J, Cirz RT, Cohen F..  (2019)  Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase..  J Med Chem,  62  (16): (7489-7505).  [PMID:31306011] [10.1021/acs.jmedchem.9b00625]
295. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B..  (2019)  Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma..  Eur J Med Chem,  163  (671-689).  [PMID:30572178] [10.1016/j.ejmech.2018.12.015]
296. Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z..  (2019)  Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase..  J Med Chem,  62  (17): (7923-7940).  [PMID:31381333] [10.1021/acs.jmedchem.9b00687]
297. Yang W, Li Y, Ai Y, Obianom ON, Guo D, Yang H, Sakamuru S, Xia M, Shu Y, Xue F..  (2019)  Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation..  J Med Chem,  62  (24): (11151-11164).  [PMID:31769984] [10.1021/acs.jmedchem.9b01252]
298. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H..  (2019)  Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952..  Bioorg Med Chem Lett,  29  (7): (873-877).  [PMID:30755337] [10.1016/j.bmcl.2019.02.006]
299. De Lucca GV, Shi Q, Liu Q, Batt DG, Beaudoin Bertrand M, Rampulla R, Mathur A, Discenza L, D'Arienzo C, Dai J, Obermeier M, Vickery R, Zhang Y, Yang Z, Marathe P, Tebben AJ, Muckelbauer JK, Chang CJ, Zhang H, Gillooly K, Taylor T, Pattoli MA, Skala S, Kukral DW, McIntyre KW, Salter-Cid L, Fura A, Burke JR, Barrish JC, Carter PH, Tino JA..  (2016)  Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)..  J Med Chem,  59  (17): (7915-7935).  [PMID:27531604] [10.1021/acs.jmedchem.6b00722]
300. Jung O, Lee J, Lee YJ, Yun JM, Son YJ, Cho JY, Ryou C, Lee SY..  (2016)  Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways..  Bioorg Med Chem Lett,  26  (16): (3963-3967).  [PMID:27422337] [10.1016/j.bmcl.2016.07.004]
301. Kaiser TM, Dentmon ZW, Dalloul CE, Sharma SK, Liotta DC..  (2020)  Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease..  ACS Med Chem Lett,  11  (4): (491-496).  [PMID:32292555] [10.1021/acsmedchemlett.9b00612]
302. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE..  (2020)  Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma..  ACS Med Chem Lett,  11  (4): (558-565).  [PMID:32292564] [10.1021/acsmedchemlett.0c00015]
303. Crawford JJ, Lee W, Johnson AR, Delatorre KJ, Chen J, Eigenbrot C, Heidmann J, Kakiuchi-Kiyota S, Katewa A, Kiefer JR, Liu L, Lubach JW, Misner D, Purkey H, Reif K, Vogt J, Wong H, Yu C, Young WB..  (2020)  Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity..  ACS Med Chem Lett,  11  (8): (1588-1597).  [PMID:32832028] [10.1021/acsmedchemlett.0c00249]
304. Zak M,Hanan EJ,Lupardus P,Brown DG,Robinson C,Siu M,Lyssikatos JP,Romero FA,Zhao G,Kellar T,Mendonca R,Ray NC,Goodacre SC,Crackett PH,McLean N,Hurley CA,Yuen PW,Cheng YX,Liu X,Liimatta M,Kohli PB,Nonomiya J,Salmon G,Buckley G,Lloyd J,Gibbons P,Ghilardi N,Kenny JR,Johnson A.  (2019)  Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling..  Bioorg Med Chem Lett,  29  (12.0): (1522-1531).  [PMID:30981576] [10.1016/j.bmcl.2019.04.008]
305. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S.  (2019)  Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group..  Bioorg Med Chem Lett,  29  (12.0): (1497-1501).  [PMID:31000154] [10.1016/j.bmcl.2019.04.014]
306. Huang W,Hulverson MA,Choi R,Arnold SLM,Zhang Z,McCloskey MC,Whitman GR,Hackman RC,Rivas KL,Barrett LK,Ojo KK,Van Voorhis WC,Fan E.  (2019)  Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy..  J Med Chem,  62  (6): (3135-3146).  [PMID:30830766] [10.1021/acs.jmedchem.9b00069]
307. Matheson, Christopher J., Coxon, Christopher R., Bayliss, Richard, Boxall, Kathy, Carbain, Benoit, Fry, Andrew M., Hardcastle, Ian R., Harnor, Suzannah J., Mas-Droux, Corine, Newell, David R., Richards, Mark W., Sivaprakasam, Mangaleswaran, Turner, David, Griffin, Roger J., Golding, Bernard T., Cano, Celine.  (2020)  2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.  RSC Med Chem,  11  (6): (707-731).  [PMID:33479670] [10.1039/d0md00074d]
308. Zhou Y,Xu X,Wang F,He H,Gong G,Xiong L,Qi B.  (2020)  Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer..  Eur J Med Chem,  204  (112643-112643).  [PMID:32731184] [10.1016/j.ejmech.2020.112643]
309. Liu J,Guiadeen D,Krikorian A,Gao X,Wang J,Boga SB,Alhassan AB,Yu Y,Vaccaro H,Liu S,Yang C,Wu H,Cooper A,de Man J,Kaptein A,Maloney K,Hornak V,Gao YD,Fischmann TO,Raaijmakers H,Vu-Pham D,Presland J,Mansueto M,Xu Z,Leccese E,Zhang-Hoover J,Knemeyer I,Garlisi CG,Bays N,Stivers P,Brandish PE,Hicks A,Kim R,Kozlowski JA.  (2016)  Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis..  ACS Med Chem Lett,  7  (2.0): (198-203).  [PMID:26985298] [10.1021/acsmedchemlett.5b00463]
310. He L,Pei H,Zhang C,Shao M,Li D,Tang M,Wang T,Chen X,Xiang M,Chen L.  (2018)  Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis..  Eur J Med Chem,  145  (96-112).  [PMID:29324347] [10.1016/j.ejmech.2017.12.079]
311. Dart ML,Machleidt T,Jost E,Schwinn MK,Robers MB,Shi C,Kirkland TA,Killoran MP,Wilkinson JM,Hartnett JR,Zimmerman K,Wood KV.  (2018)  Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift..  ACS Med Chem Lett,  9  (6.0): (546-551).  [PMID:29937980] [10.1021/acsmedchemlett.8b00081]
312. Kaoud TS,Mohassab AM,Hassan HA,Yan C,Van Ravenstein SX,Abdelhamid D,Dalby KN,Abdel-Aziz M.  (2020)  NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth..  Eur J Med Chem,  186  (111885-111885).  [PMID:31784187] [10.1016/j.ejmech.2019.111885]
313. Elwaie TA,Abbas SE,Aly EI,George RF,Ali H,Kraiouchkine N,Abdelwahed KS,Fandy TE,El Sayed KA,Abd Elmageed ZY,Ali HI.  (2020)  HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability..  J Med Chem,  63  (24.0): (15906-15945).  [PMID:33314925] [10.1021/acs.jmedchem.0c01647]
314. Liu J,Guiadeen D,Krikorian A,Gao X,Wang J,Babu Boga S,Alhassan AB,Yu W,Selyutin O,Yu Y,Anand R,Xu J,Kelly J,Duffy JL,Liu S,Yang C,Wu H,Cai J,Bennett C,Maloney KM,Tyagarajan S,Gao YD,Fischmann TO,Presland J,Mansueto M,Xu Z,Leccese E,Zhang-Hoover J,Knemeyer I,Garlisi CG,Stivers P,Brandish PE,Hicks A,Kim R,Kozlowski JA.  (2020)  Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes..  Bioorg Med Chem Lett,  30  (17): (127390-127390).  [PMID:32738973] [10.1016/j.bmcl.2020.127390]
315. Srour AM,Ahmed NS,Abd El-Karim SS,Anwar MM,El-Hallouty SM.  (2020)  Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors..  Bioorg Med Chem,  28  (18): (115657-115657).  [PMID:32828424] [10.1016/j.bmc.2020.115657]
316. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY.  (2018)  Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants..  Eur J Med Chem,  143  (1148-1164).  [PMID:29133048] [10.1016/j.ejmech.2017.09.018]
317. Chen Y,Bai G,Ning Y,Cai S,Zhang T,Song P,Zhou J,Duan W,Ding J,Xie H,Zhang H.  (2020)  Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma..  Eur J Med Chem,  190  (112092-112092).  [PMID:32014679] [10.1016/j.ejmech.2020.112092]
318. Jeong P,Moon Y,Lee JH,Lee SD,Park J,Lee J,Kim J,Lee HJ,Kim NY,Choi J,Heo JD,Shin JE,Park HW,Kim YG,Han SY,Kim YC.  (2020)  Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia..  Eur J Med Chem,  195  (112205-112205).  [PMID:32272419] [10.1016/j.ejmech.2020.112205]
319. Teng Y,Lu X,Xiao M,Li Z,Zou Y,Ren S,Cheng Y,Luo G,Xiang H.  (2020)  Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold..  Eur J Med Chem,  199  (112339-112339).  [PMID:32402933] [10.1016/j.ejmech.2020.112339]
320. El-Damasy AK,Jin H,Seo SH,Bang EK,Keum G.  (2020)  Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity..  Eur J Med Chem,  207  (112710-112710).  [PMID:32961435] [10.1016/j.ejmech.2020.112710]
321. Krajčovičová S, Jorda R, Vanda D, Soural M, Kryštof V..  (2021)  1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase..  Eur J Med Chem,  211  (113094-113094).  [PMID:33340912] [10.1016/j.ejmech.2020.113094]
322. Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H..  (2022)  Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors..  J Med Chem,  65  (2.0): (1243-1264).  [PMID:33586434] [10.1021/acs.jmedchem.0c02111]
323. Pyper, J M JM and Bolen, J B JB..  (1990)  Identification of a novel neuronal C-SRC exon expressed in human brain..  Molecular and cellular biology,      [PMID:1691439]
324. Cartwright, C A CA, Kamps, M P MP, Meisler, A I AI, Pipas, J M JM and Eckhart, W W..  (1989)  pp60c-src activation in human colon carcinoma..  The Journal of clinical investigation,      [PMID:2498394]
325. Parker, R C RC, Mardon, G G, Lebo, R V RV, Varmus, H E HE and Bishop, J M JM..  (1985)  Isolation of duplicated human c-src genes located on chromosomes 1 and 20..  Molecular and cellular biology,      [PMID:2581127]
326. Anderson, S K SK, Gibbs, C P CP, Tanaka, A A, Kung, H J HJ and Fujita, D J DJ..  (1985)  Human cellular src gene: nucleotide sequence and derived amino acid sequence of the region coding for the carboxy-terminal two-thirds of pp60c-src..  Molecular and cellular biology,      [PMID:2582238]
327. Pyper, J M JM and Bolen, J B JB..  (1989)  Neuron-specific splicing of C-SRC RNA in human brain..  Journal of neuroscience research,      [PMID:2681803]
328. Rosen, N N and 5 more authors..  (1986)  Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues..  The Journal of biological chemistry,    (15):   [PMID:3093483]
329. Tanaka, A A and 5 more authors..  (1987)  DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes..  Molecular and cellular biology,      [PMID:3299057]
330. Brümmer, J J, Neumaier, M M, Göpfert, C C and Wagener, C C..  (1995)  Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion molecule of the carcinoembryonic antigen family downregulated in colorectal carcinomas..  Oncogene,    (19):   [PMID:7478590]
331. Xu, R X RX and 5 more authors..  (1995)  Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide..  Biochemistry,    (21):   [PMID:7532003]
332. Matsunaga, T T and 5 more authors..  (1993)  Expression of alternatively spliced src messenger RNAs related to neuronal differentiation in human neuroblastomas..  Cancer research,    (1):   [PMID:8319227]
333. Charifson, P S PS and 10 more authors..  (1997)  Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic and structural study..  Biochemistry,    (27):   [PMID:9174343]
334. Chang, B Y BY, Conroy, K B KB, Machleder, E M EM and Cartwright, C A CA..  (1998)  RACK1, a receptor for activated C kinase and a homolog of the beta subunit of G proteins, inhibits activity of src tyrosine kinases and growth of NIH 3T3 cells..  Molecular and cellular biology,      [PMID:9584165]
335. Luttrell, L M LM and 11 more authors..  (1999)  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes..  Science (New York, N.Y.),    (29):   [PMID:9924018]
336. Rebhun, J F JF, Chen, H H and Quilliam, L A LA..  (2000)  Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase Ral..  The Journal of biological chemistry,    (5):   [PMID:10747847]
337. Miller, W E WE and 5 more authors..  (2000)  beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in receptor endocytosis..  The Journal of biological chemistry,    (14):   [PMID:10753943]
338. Li, Y Y, Kuwahara, H H, Ren, J J, Wen, G G and Kufe, D D..  (2001)  The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin..  The Journal of biological chemistry,    (2):   [PMID:11152665]
339. Chang, B Y BY, Chiang, M M and Cartwright, C A CA..  (2001)  The interaction of Src and RACK1 is enhanced by activation of protein kinase C and tyrosine phosphorylation of RACK1..  The Journal of biological chemistry,    (8):   [PMID:11279199]
340. Giglione, C C, Gonfloni, S S and Parmeggiani, A A..  (2001)  Differential actions of p60c-Src and Lck kinases on the Ras regulators p120-GAP and GDP/GTP exchange factor CDC25Mm..  European journal of biochemistry,      [PMID:11389730]
341. Korkaya, H H and 11 more authors..  (2001)  The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK..  The Journal of biological chemistry,    (9):   [PMID:11518702]
342. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ..  (2002)  TTD: Therapeutic Target Database..  Nucleic acids research,    (1):   [PMID:11752352]
343. Lee, Hyangkyu H and 5 more authors..  (2002)  Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phospho-caveolin-2 (Tyr(P)19) is localized near focal adhesions, remains associated with lipid rafts/caveolae, but no longer forms a high molecular mass hetero-oligomer with caveolin-1..  The Journal of biological chemistry,    (13):   [PMID:12091389]
344. Miyazaki, Tsuyoshi T, Neff, Lynn L, Tanaka, Sakae S, Horne, William C WC and Baron, Roland R..  (2003)  Regulation of cytochrome c oxidase activity by c-Src in osteoclasts..  The Journal of cell biology,    (3):   [PMID:12615910]
345. Vindis, Cecile C, Cerretti, Douglas Pat DP, Daniel, Thomas O TO and Huynh-Do, Uyen U..  (2003)  EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote chemotaxis..  The Journal of cell biology,    (18):   [PMID:12925710]
346. Taniyama, Yoshihiro Y and 8 more authors..  (2003)  Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal adhesions..  Molecular and cellular biology,      [PMID:14585963]
347. Kamath, J R JR, Liu, R R, Enstrom, A M AM, Lou, Q Q and Lam, K S KS..  (2003)  Development and characterization of potent and specific peptide inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach..  The journal of peptide research : official journal of the American Peptide Society,      [PMID:14632929]
348. Kim, Minsoo M, Tezuka, Tohru T, Tanaka, Keiji K and Yamamoto, Tadashi T..  (2004)  Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation..  Oncogene,    (4):   [PMID:14661060]
349. Barletta, Frank F and 5 more authors..  (2004)  Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc..  Molecular endocrinology (Baltimore, Md.),      [PMID:14963108]
350. Wang, Xiao Bo XB and 7 more authors..  (2004)  Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27)..  Biochemistry,    (2):   [PMID:15504032]
351. Benes, Cyril H CH and 5 more authors..  (2005)  The C2 domain of PKCdelta is a phosphotyrosine binding domain..  Cell,    (22):   [PMID:15851033]
352. Yang, Kyungmi K and 5 more authors..  (2005)  Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation..  The Journal of biological chemistry,    (25):   [PMID:16186108]
353. Nam, Sangkil S and 8 more authors..  (2005)  Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells..  Cancer research,    (15):   [PMID:16230377]
354. Schittenhelm, Marcus M MM and 9 more authors..  (2006)  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies..  Cancer research,    (1):   [PMID:16397263]
355. Franco, Mélanie M and 5 more authors..  (2006)  The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors..  Molecular and cellular biology,      [PMID:16479011]
356. Dalgarno, David D and 19 more authors..  (2006)  Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds..  Chemical biology & drug design,      [PMID:16492148]
357. Serrels, Alan A and 8 more authors..  (2006)  Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib..  Molecular cancer therapeutics,      [PMID:17148760]
358. Quintás-Cardama, Alfonso A, Kantarjian, Hagop H and Cortes, Jorge J..  (2006)  Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib..  Future oncology (London, England),      [PMID:17155893]
359. Maudsley, Stuart S and 6 more authors..  (2006)  Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5..  Neuroendocrinology,      [PMID:17202804]
360. Kamath, Amrita V; Wang, Jian; Lee, Francis Y and Marathe, Punit H..  (2008)  Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL..  Cancer chemotherapy and pharmacology,      [PMID:17429625]
361. Di Stefano, Paola P and 12 more authors..  (2007)  p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity..  The EMBO journal,    (20):   [PMID:17525734]
362. Yang, Keum-Jin KJ and 15 more authors..  (2008)  Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding..  The Journal of biological chemistry,    (18):   [PMID:18024423]
363. Zahedi, René P RP and 8 more authors..  (2008)  Phosphoproteome of resting human platelets..  Journal of proteome research,      [PMID:18088087]
364. Daub, Henrik H and 9 more authors..  (2008)  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle..  Molecular cell,    (8):   [PMID:18691976]
365. Chabot, Catherine C, Spring, Kathleen K, Gratton, Jean-Philippe JP, Elchebly, Mounib M and Royal, Isabelle I..  (2009)  New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival..  Molecular and cellular biology,      [PMID:18936167]
366. Zhang, Yongjun Y, Tu, Yizeng Y, Zhao, Jianping J, Chen, Ka K and Wu, Chuanyue C..  (2009)  Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle..  The Journal of cell biology,    (23):   [PMID:19307596]
367. Johnsen, Ingvild B IB, Nguyen, Thuy Thanh TT, Bergstroem, Bjarte B, Fitzgerald, Katherine A KA and Anthonsen, Marit W MW..  (2009)  The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)-elicited antiviral signaling..  The Journal of biological chemistry,    (10):   [PMID:19419966]
368. Baumgartner, Martin M, Weiss, Andreas A, Fritzius, Thorsten T, Heinrich, Jochen J and Moelling, Karin K..  (2009)  The PDZ protein MPP2 interacts with c-Src in epithelial cells..  Experimental cell research,    (15):   [PMID:19665017]
369. Mayya, Viveka V and 7 more authors..  (2009)  Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions..  Science signaling,    (18):   [PMID:19690332]
370. Voss, Matthias M, Lettau, Marcus M and Janssen, Ottmar O..  (2009)  Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening..  BMC immunology,    (6):   [PMID:19807924]
371. Zhou, Tianjun T and 8 more authors..  (2010)  Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template..  Chemical biology & drug design,      [PMID:19895503]
372. Goh, Yun-Mi YM and 12 more authors..  (2010)  Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm..  The Journal of biological chemistry,    (26):   [PMID:20100835]
373. Ryan, Philip E PE, Sivadasan-Nair, Nina N, Nau, Marion M MM, Nicholas, Sarah S and Lipkowitz, Stanley S..  (2010)  The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin-conjugating enzyme..  The Journal of biological chemistry,    (30):   [PMID:20525694]
374. Mund, Thomas T and Pelham, Hugh R B HR..  (2010)  Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin ligase activators Ndfip1 and Ndfip2..  Proceedings of the National Academy of Sciences of the United States of America,    (22):   [PMID:20534535]
375. Yao, Xiao X, Balamurugan, Parimaladevi P, Arvey, Aaron A, Leslie, Christina C and Zhang, Li L..  (2010)  Heme controls the regulation of protein tyrosine kinases Jak2 and Src..  Biochemical and biophysical research communications,    (3):   [PMID:21036157]
376. Chan, Wing W, Sit, Soon-Tuck ST and Manser, Ed E..  (2011)  The Cdc42-associated kinase ACK1 is not autoinhibited but requires Src for activation..  The Biochemical journal,    (15):   [PMID:21309750]
377. Wang, Yu Y, Cao, Hong H, Chen, Jing J and McNiven, Mark A MA..  (2011)  A direct interaction between the large GTPase dynamin-2 and FAK regulates focal adhesion dynamics in response to active Src..  Molecular biology of the cell,      [PMID:21411625]
378. Hrdinka, Matous M and 9 more authors..  (2011)  PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis..  The Journal of biological chemistry,    (3):   [PMID:21460222]
379. Zhang, P P and 8 more authors..  (2013)  Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14..  Oncogene,    (18):   [PMID:22710723]
380. Takeshita, Kohei K and 8 more authors..  (2012)  Structural flexibility regulates phosphopeptide-binding activity of the tyrosine kinase binding domain of Cbl-c..  Journal of biochemistry,      [PMID:22888118]
381. Antonarakis, Emmanuel S ES and 12 more authors..  (2013)  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer..  Cancer chemotherapy and pharmacology,      [PMID:23314737]
382. Yoshida, Soichiro S and 20 more authors..  (2013)  Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis..  Proceedings of the National Academy of Sciences of the United States of America,    (23):   [PMID:23564345]
383. Wilbek, Theis S and 5 more authors..  (2015)  Identification and characterization of a small-molecule inhibitor of death-associated protein kinase 1..  Chembiochem : a European journal of chemical biology,    (2):   [PMID:25382253]
384. Taniguchi, Koji K and 17 more authors..  (2015)  A gp130-Src-YAP module links inflammation to epithelial regeneration..  Nature,    (5):   [PMID:25731159]
385. Terai, Hideki H and 7 more authors..  (2015)  Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer..  ACS chemical biology,    (18):   [PMID:26390252]
386. Turro, Ernest E and 43 more authors..  (2016)  A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies..  Science translational medicine,    (2):   [PMID:26936507]
387. Lu, Yilu Y and 7 more authors..  (2017)  Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating the stability and activity of BMAL1 and CLOCK..  Oncotarget,    (15):   [PMID:28903391]
388. Wind, Sven and 7 more authors..  (2019)  Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib..  Clinical pharmacokinetics,      [PMID:31016670]
389. Wang, Lei L, Wen, Mingyue M and Cao, Xuetao X..  (2019)  Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses..  Science (New York, N.Y.),    (16):   [PMID:31320558]
390. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC.  (2018)  Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity..  Bioorg Med Chem Lett,  28  (10): (1964-1971).  [PMID:29636220] [10.1016/j.bmcl.2018.03.032]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.